Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Farletuzumab plus weekly paclitaxel versus placebo plus weekly paclitaxel in platinum-resistant or refractory relapsed ovarian cancer
NL-OMON35492Phase 2Active, not recruiting
- Sponsor
- Morphotek
- Start
- Sep 2010
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) comparing Farletuzumab + paclitaxel with Placebo + paclitaxel (2 arms). Primary endpoint: Progression-free survival. Started Sep 2010; status: active, not recruiting.
02
Drugs
farletuzumabpaclitaxel
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NL-OMON35492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35492.